75% of the population
Treated by Brazil's Universal Healthcare System
of Total Investments in R&D in the Country
Pharmaceutical Market in the World
Private Health Market in the World
80 to 85 years old
Projected Life Expectancy
Health and Life Sciences in Brazil
Being one of the world's largest economies, with the sixth largest population on the planet (over 220 million people), Brazil still has about one-third of its population under the age of 20, while the average life expectancy is 76 years old. Estimates from the Brazilian Institute of Geography and Statistics (IBGE) indicate that, by 2060, people over 65 years old will account for 25.5% of the population
Brazil has both public and private healthcare systems. The universal public system, known as SUS (Sistema Único de Saúde), accounts for almost half of total healthcare spending and treats 75% of the population. Brazil is one of the few countries with a population of more than 100 million people that provides universal and free healthcare, and the challenges of operating a universal healthcare system in the world’s sixth-largest country by population are immense. Brazil also has the third largest private health market in the world, with expenditures of USD 102 billion, representing 55.6% of the total spent on health in the country.
In addition, the market revenue for pharmaceutical companies grew 8% in 2018, to a total of BRL 103.4 billion (USD 28.3 billion), with some 60% of this coming from retail. Brazil is also a leading market for the production and consumption of generic drugs, which have price discounts of up to 65% compared to brand name drugs in the country.
Brazil has a great potential for those looking to diversify investments in Life Sciences, with a market that offers both scale and robust growth rates over the medium and long-term. The fundamentals that drive the market in the Life Sciences industry include the size of Brazil’s population and consumer market, growing healthcare expenditures in both public and private services, and the gradual shift to an older population. Health expenditure in Brazil is estimated at USD 237 billion in 2018. In 2028, Brazil is expected to remain amid the top 10 markets, with estimated expenditures of USD 333.1 billion.
- SUS (Sistema Único de Saúde) accounts for almost half of total healthcare spending and treats 75% of the population;
- The health industry is among the most innovative in the world, and in Brazil it accounts for 35% of the total invested in R&D;
- Brazil ranks as the 6th largest pharmaceutical market in the world;
- Brazil has the third largest private health market in the world, with expenditures of USD 102 billion, representing 55.6% of the total spent on health in the country;
- Life expectancy is projected to be 80 to 85 years old by 2060.
Apex-Brasil and the Covid-19 crisis.
Roberto Escoto, Apex-Brasil’s Head of Investment, has a message for you. Watch the video and learn how Apex-Brasil is supporting foreign investors during the Covid-19 crisis.
Investments in the Health Industry and the Covid-19 Crisis
Brazilian Pharma & Health was born to expand the participation of companies in the production chains of pharmochemical, pharmaceutical and biotechnological medicines for human and animal health in the Brazilian international scene. The project is carried out by Abiquifi (Brazilian Pharmaceutical Input Industry Association) in partnership with Apex-Brasil.
Brazilian Health Devices
The program Brazilian Health Devices implemented by Apex-Brazil in partnership with ABIMO (Brazilian Medical Devices Manufacturers Association), has the purpose to foster Brazilian medical device health industry internationally.
Apex-Brasil has been assisting health foreign investors since 2017. We work in close cooperation with relevant public and private stakeholders in order to help you achieve the best results for your investment plan.